These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38225212)

  • 1. Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test.
    McRae MP; Kittelson J; Helmke SM; Everson GT
    Basic Clin Pharmacol Toxicol; 2024 Mar; 134(3):385-395. PubMed ID: 38225212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Within-individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test.
    McRae MP; Kittelson J; Helmke SM; Everson GT
    Clin Transl Sci; 2024 Apr; 17(4):e13786. PubMed ID: 38558534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child-Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine.
    Kanodia J; Giovinazzo H; Yates W; Bourdet DL; McRae MP; Helmke SM; Everson GT
    Clin Pharmacol Ther; 2024 Jul; 116(1):186-193. PubMed ID: 38654484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver function and portal-systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.
    Hassanein T; Keaveny AP; Mantry P; Smith AD; McRae MP; Kittelson J; Helmke S; Everson GT;
    Aliment Pharmacol Ther; 2024 Jul; 60(2):246-256. PubMed ID: 38778481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test.
    Lawitz EJ; Ertle J; Schoelch C; Gashaw I; McRae MP; Helmke SM; Everson GT
    Liver Transpl; 2024 Oct; 30(10):982-990. PubMed ID: 38869987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology.
    Burton JR; Helmke S; Lauriski S; Kittelson J; Everson GT
    Transl Res; 2021 Jul; 233():5-15. PubMed ID: 33400995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing hepatic impairment in Fontan-associated liver disease using the HepQuant SHUNT test.
    Lemmer A; VanWagner L; Gasanova Z; Helmke S; Everson GT; Ganger D
    Congenit Heart Dis; 2019 Nov; 14(6):978-986. PubMed ID: 31369200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt.
    Everson GT; Martucci MA; Shiffman ML; Sterling RK; Morgan TR; Hoefs JC;
    Aliment Pharmacol Ther; 2007 Aug; 26(3):401-10. PubMed ID: 17635375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compartmental model describing the physiological basis for the HepQuant SHUNT test.
    McRae MP; Helmke SM; Burton JR; Everson GT
    Transl Res; 2023 Feb; 252():53-63. PubMed ID: 35948199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease.
    Wieland A; Etzion O; Ali RO; Levy E; Kleiner DE; Helmke SM; Heller T; Everson GT
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e890-e894. PubMed ID: 33895359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting clinical decompensation in patients with cirrhosis using the Hepquant-SHUNT test.
    Fallahzadeh MA; Hansen DJ; Trotter JF; Everson GT; Saracino G; Rahimi RS; Helmke S; Boutte J; Asrani SK
    Aliment Pharmacol Ther; 2021 Apr; 53(8):928-938. PubMed ID: 33556192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Validated LC-MS/MS Assay for the Quantification of Cholate Isotopes in Human Serum.
    Helmke SM; McRae MP; Christians U; Shokati T; Everson GT
    J Appl Lab Med; 2024 Aug; ():. PubMed ID: 39150903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial.
    Everson GT; Shiffman ML; Morgan TR; Hoefs JC; Sterling RK; Wagner DA; Kulig CC; Curto TM; Wright EC;
    Aliment Pharmacol Ther; 2008 May; 27(9):798-809. PubMed ID: 18266997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
    Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL
    Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT test.
    Maan R; Sonneveld MJ
    Aliment Pharmacol Ther; 2021 Apr; 53(8):939-940. PubMed ID: 33745172
    [No Abstract]   [Full Text] [Related]  

  • 16. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hepatopulmonary syndrome in liver cirrhosis].
    Culafić Dj; Perisić M; Rebić P
    Srp Arh Celok Lek; 2000; 128(7-8):271-5. PubMed ID: 11089435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis.
    Shrestha R; McKinley C; Showalter R; Wilner K; Marsano L; Vivian B; Everson GT
    Liver Transpl Surg; 1997 Mar; 3(2):166-73. PubMed ID: 9346731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: stratifying risk of adverse outcomes in cirrhosis-the Hepquant SHUNT test. Authors' reply.
    Asrani SK; Everson GT
    Aliment Pharmacol Ther; 2021 Apr; 53(8):941-942. PubMed ID: 33745171
    [No Abstract]   [Full Text] [Related]  

  • 20. A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent-shunt.
    Jalan R; Gooday R; O'Carroll RE; Redhead DN; Elton RA; Hayes PC
    J Hepatol; 1995 Dec; 23(6):697-705. PubMed ID: 8750169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.